This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reubi, J. C. Articles by Laissue, J. A. Search for Related Content PubMed PubMed Citation Articles by Reubi, J. C. Articles by Laissue, J. A.

Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin¹

Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland [J. C. R., U. L., B. W., J. A. L.]; Institute of Pathology, Kantonsspital Luzern, CH-6000 Luzern, Switzerland [J-O. G.]; and Departement de Chimie Biologique et de la Nutrition, Université Libre de Bruxelles, B-1070 Bruxelles, Belgium [P. R.]

The evaluation of peptide receptors in man is needed not only to discover the physiological target tissues of a given peptide but also to identify diseases with a sufficient receptor overexpression for diagnostic or therapeutic interventions. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been evaluated in human tumors and in their tissues of origin using in vitro receptor autoradiography with ¹²⁵I-VIP or ¹²⁵I-acetyl-PACAP-27 in tissue sections. The VIP/PACAP receptor subtypes VPAC₁, VPAC₂, and PAC₁ were evaluated in these tissues by determining the rank order of potencies of VIP and PACAP as well as VPAC₁- and VPAC₂-selective analogues. The VIP/PACAP receptors expressed in the great majority of the most frequently occurring human tumors, including breast (100% receptor incidence), prostate (100%), pancreas (65%), lung (58%), colon (96%), stomach (54%), liver (49%), and urinary bladder (100%) carcinomas as well as lymphomas (58%) and meningiomas (100%), are predominantly of the VPAC₁ type. Their cells or tissues of origin, i.e., hepatocytes, breast lobules and ducts, urothelium, prostate glands, pancreatic ducts, lung acini, gastrointestinal mucosa, and lymphocytes, also predominantly express VPAC₁. Leiomyomas predominantly express VPAC₂ receptors, whereas paragangliomas, pheochromocytomas, and endometrial carcinomas preferentially express PAC₁ receptors. Conversely, VPAC₂ receptors are found mainly in smooth muscle (i.e., stomach), in vessels, and in stroma (e.g., of the prostate), whereas PAC₁ receptors are present in the adrenal medulla and in some uterine glands. Whereas the very wide distribution of VIP/PACAP receptors in the normal human body is indicative of a key role of these peptides in human physiology, the high VIP/PACAP receptor expression in tumors may represent the molecular basis for clinical applications of VIP/PACAP such as in vivo scintigraphy and radiotherapy of tumors as well as VIP/PACAP analogue treatment for tumor growth inhibition.

This article has been cited by other articles:

				K. Zhang, M. R. Aruva, N. Shanthly, C. A. Cardi, S. Rattan, C. Patel, C. Kim, P. A. McCue, E. Wickstrom, and M. L. Thakur PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer J. Nucl. Med., January 1, 2008; 49(1): 112 - 121. [Abstract] [Full Text] [PDF]

				T. S. Steigedal, T. Bruland, K. Misund, L. Thommesen, and A. Laegreid Inducible cAMP early repressor suppresses gastrin-mediated activation of cyclin D1 and c-fos gene expression Am J Physiol Gastrointest Liver Physiol, April 1, 2007; 292(4): G1062 - G1069. [Abstract] [Full Text] [PDF]

				D. Wild, M. Behe, A. Wicki, D. Storch, B. Waser, M. Gotthardt, B. Keil, G. Christofori, J. C. Reubi, and H. R. Macke [Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a Very Promising Ligand for Glucagon-like Peptide-1 (GLP-1) Receptor Targeting J. Nucl. Med., December 1, 2006; 47(12): 2025 - 2033. [Abstract] [Full Text] [PDF]

				M. Korner, G. M. Hayes, R. Rehmann, A. Zimmermann, H. Friess, L. J. Miller, and J. C. Reubi Secretin Receptors in Normal and Diseased Human Pancreas: Marked Reduction of Receptor Binding in Ductal Neoplasia Am. J. Pathol., October 1, 2005; 167(4): 959 - 968. [Abstract] [Full Text] [PDF]

				J. C. Reubi, H. R. Macke, and E. P. Krenning Candidates for Peptide Receptor Radiotherapy Today and in the Future J. Nucl. Med., January 1, 2005; 46(1_suppl): 67S - 75S. [Abstract] [Full Text] [PDF]

				S. Schulz, C. Rocken, C. Mawrin, W. Weise, V. Hollt, and S. Schulz Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies Clin. Cancer Res., December 15, 2004; 10(24): 8235 - 8242. [Abstract] [Full Text] [PDF]

				M. L. Thakur, M. R. Aruva, J. Gariepy, P. Acton, S. Rattan, S. Prasad, E. Wickstrom, and A. Alavi PET Imaging of Oncogene Overexpression Using 64Cu-Vasoactive Intestinal Peptide (VIP) Analog: Comparison with 99mTc-VIP Analog J. Nucl. Med., August 1, 2004; 45(8): 1381 - 1389. [Abstract] [Full Text] [PDF]

				A. J. Harmar, W. J. Sheward, C. F. Morrison, B. Waser, M. Gugger, and J. C. Reubi Distribution of the VPAC2 Receptor in Peripheral Tissues of the Mouse Endocrinology, March 1, 2004; 145(3): 1203 - 1210. [Abstract] [Full Text] [PDF]

				Z. Szereday, A. V. Schally, J. L. Varga, C. A. Kanashiro, F. Hebert, P. Armatis, K. Groot, K. Szepeshazi, G. Halmos, and R. Busto Antagonists of Growth Hormone-Releasing Hormone Inhibit the Proliferation of Experimental Non-Small Cell Lung Carcinoma Cancer Res., November 15, 2003; 63(22): 7913 - 7919. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				J. C. Reubi, B. Waser, W. Vale, and J. Rivier Expression of CRF1 and CRF2 Receptors in Human Cancers J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3312 - 3320. [Abstract] [Full Text] [PDF]

				L. Grumolato, A. G. Elkahloun, H. Ghzili, D. Alexandre, C. Coulouarn, L. Yon, J.-P. Salier, L. E. Eiden, A. Fournier, H. Vaudry, et al. Microarray and Suppression Subtractive Hybridization Analyses of Gene Expression in Pheochromocytoma Cells Reveal Pleiotropic Effects of Pituitary Adenylate Cyclase-Activating Polypeptide on Cell Proliferation, Survival, and Adhesion Endocrinology, June 1, 2003; 144(6): 2368 - 2379. [Abstract] [Full Text] [PDF]

				D. Farini, A. Puglianiello, C. Mammi, G. Siracusa, and C. Moretti Dual Effect of Pituitary Adenylate Cyclase Activating Polypeptide on Prostate Tumor LNCaP Cells: Short- and Long-Term Exposure Affect Proliferation and Neuroendocrine Differentiation Endocrinology, April 1, 2003; 144(4): 1631 - 1643. [Abstract] [Full Text] [PDF]

				H. Igarashi, T. Ito, T. K. Pradhan, S. A. Mantey, W. Hou, D. H. Coy, and R. T. Jensen Elucidation of the Vasoactive Intestinal Peptide Pharmacophore for VPAC2 Receptors in Human and Rat and Comparison to the Pharmacophore for VPAC1 Receptors J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 445 - 460. [Abstract] [Full Text] [PDF]

				N. Belousova, V. Krendelchtchikova, D. T. Curiel, and V. Krasnykh Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein J. Virol., July 29, 2002; 76(17): 8621 - 8631. [Abstract] [Full Text] [PDF]

				H. Igarashi, T. Ito, W. Hou, S. A. Mantey, T. K. Pradhan, C. D. Ulrich II, S. J. Hocart, D. H. Coy, and R. T. Jensen Elucidation of Vasoactive Intestinal Peptide Pharmacophore for VPAC1 Receptors in Human, Rat, and Guinea Pig J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 37 - 50. [Abstract] [Full Text] [PDF]

				J. C. Reubi, M. Gugger, B. Waser, and J.-C. Schaer Y1-Mediated Effect of Neuropeptide Y in Cancer: Breast Carcinomas as Targets Cancer Res., June 1, 2001; 61(11): 4636 - 4641. [Abstract] [Full Text] [PDF]